Review Article

Immunogenicity and Personalized Medicine: Shaping Tailored Therapies for Better Patient Outcomes

Nidhi Kumar[1], Pooja Prasad[2]

[1,2]Devaki Amma Memorial College of Pharmacy, Malappuram, Kerala, India

I N F O

A B S T R A C T

Immunogenicity, the ability of a therapeutic agent to provoke an immune response, poses significant challenges in the field of medicine, particularly in the treatment of diseases using biologic agents such as monoclonal antibodies, vaccines, and gene therapies. As the field of personalized medicine advances, understanding the role of immunogenicity is crucial in optimizing treatment outcomes. Personalized medicine tailors therapies based on individual patient characteristics, including genetic, environmental, and lifestyle factors. This review explores how immunogenicity impacts the effectiveness and safety of biologic therapies and its integration into personalized medicine. By leveraging genetic profiling, biomarker discovery, and novel therapeutic designs, it is possible to reduce the risks of immune responses and enhance treatment efficacy. Through understanding the immunogenic profile of patients, healthcare providers can make informed decisions to offer more effective, individualized treatments, thus improving patient outcomes. This review also examines current strategies aimed at mitigating immunogenicity in biologic therapies, including the engineering of biologics, immunosuppressive protocols, and the role of pharmacogenomics in customizing treatments.

Keywords: Immunogenicity, Personalized Medicine, Biologic Therapies, Monoclonal Antibodies, Gene Therapy, Genetic Profiling, Immunosuppression, Tailored Treatment, Pharmacogenomics, Patient Outcomes

Introduction

Personalized medicine is revolutionizing healthcare by customizing treatments based on the genetic, environmental, and lifestyle factors of individual patients. A key component of this approach is the increasing use of biologic agents, such as monoclonal antibodies (mAbs), vaccines, and gene therapies, which have transformed the treatment of numerous diseases, including cancer, autoimmune disorders, and infectious diseases. However, one significant challenge with biologic therapies is immunogenicity—the ability of these agents to provoke immune responses in patients. These immune responses can lead to the formation of anti-drug antibodies (ADAs), reduced drug efficacy, or even adverse events, which complicate treatment regimens and compromise patient outcomes.

This review highlights the role of immunogenicity in personalized medicine and its implications for tailoring

Kumar N & Prasad P
Rec. Trends Pharm. Tech. Ind. 2025; 7(1)

44

therapies to improve patient outcomes.[1] By understanding the factors that contribute to immunogenicity, such as genetic variation, protein structure, and the patient's immune system, clinicians can optimize biologic therapies for individual patients. The review discusses recent advancements in immunogenicity testing, strategies to minimize immune responses, and the integration of pharmacogenomic data into therapeutic decision-making.

Immunogenicity and its Impact on Biologic Therapies

Immunogenicity is a key concern in the development and clinical use of biologic therapies, especially monoclonal antibodies (mAbs), recombinant proteins, vaccines, and gene therapies. Immunogenicity refers to the ability of a biologic product to elicit an immune response in the patient, which can lead to the formation of anti-drug antibodies (ADAs). These antibodies may neutralize the therapeutic effects of the biologic, result in hypersensitivity reactions, or cause adverse clinical outcomes, complicating treatment and patient management.[2] As biologic therapies are typically derived from human or animal sources, the immune system may recognize these therapeutic agents as foreign, triggering immune activation.

Mechanisms of Immunogenicity

The immune response to biologics can involve both the innate and adaptive immune systems. Biologics are usually large, complex molecules that may be perceived by the immune system as non-self. The immune system's recognition of these agents can lead to the activation of T cells, which in turn promote the production of antibodies. The mechanisms of immunogenicity are multifactorial and depend on the following:

- **Antigenicity:** The more foreign or non-human the therapeutic molecule is, the greater the likelihood that the immune system will generate an immune response. For example, chimeric monoclonal antibodies (mAbs), which contain both human and animal components, are more likely to elicit immune responses than fully human mAbs.
- **Molecular Size and Complexity:** Larger, more complex molecules are often more immunogenic than smaller molecules. This is because they present more epitopes (specific regions recognized by the immune system) to immune cells, increasing the chances of immune activation.
- **Glycosylation Patterns:** Glycosylation, the process by which sugar molecules are attached to the protein backbone, can also influence the immunogenicity of biologics. Differences in glycosylation patterns between therapeutic proteins and endogenous human proteins can lead to immune activation.
- **Conformation and Aggregation:** The three-dimensional structure of biologics can affect their immunogenic

potential. Misfolded proteins or aggregates formed during production can be recognized as abnormal by the immune system, triggering a response.

Types of Immune Responses

The immune response to biologics can range from mild to severe, depending on various factors, including the specific biologic used and the patient's immune system. Key immune responses include:

- **Anti-Drug Antibodies (ADAs):** ADAs are antibodies produced by the patient's immune system in response to the biologic drug.[3] These antibodies can neutralize the therapeutic agent, leading to reduced efficacy or complete treatment failure. In some cases, ADAs can also cause hypersensitivity reactions, such as rash, fever, or even anaphylaxis.
- **Hypersensitivity Reactions:** These are immediate or delayed immune responses that can cause symptoms ranging from mild rashes and fever to life-threatening anaphylaxis. Such reactions can be triggered by the biologic itself or by excipients used in the formulation.
- **Complement Activation:** In some cases, the immune response to biologics can lead to activation of the complement system, a part of the innate immune response. This can cause inflammation, tissue damage, and other adverse effects.
- **T-cell Responses:** T-cell activation, particularly in the context of gene therapies or vaccines, can lead to immune responses against the therapeutic agent, including cytotoxic T lymphocyte-mediated destruction of cells expressing the therapeutic protein.

Impact of Immunogenicity on Biologic Therapy Outcomes

Immunogenicity can significantly affect the clinical outcomes of biologic therapies in several ways:

- **Loss of Efficacy:** The presence of ADAs can neutralize the biologic or reduce its therapeutic activity, leading to loss of efficacy. For example, in the case of monoclonal antibodies, ADAs may bind to the therapeutic antibody and prevent it from interacting with its target, such as a cancer cell or virus.
- **Adverse Reactions:** Immune responses can lead to severe allergic reactions, including anaphylaxis, which can be life-threatening.[4] In addition, immune responses may cause serum sickness, organ toxicity, or infusion-related reactions, which may require dose adjustments or discontinuation of treatment.
- **Altered Pharmacokinetics:** The formation of ADAs can influence the pharmacokinetics (PK) of the biologic, such as its clearance rate from the body. For instance, the presence of ADAs may accelerate the clearance of the biologic, reducing its plasma half-life and requiring more frequent dosing.

45

Kumar N & Prasad P
Rec. Trends Pharm. Tech. Ind. 2025; 7(1)

- **Cross-Reactivity:** In some instances, ADAs against a biologic may cross-react with other biologics or even the patient's own proteins, potentially leading to autoimmunity or other immunologic complications.

Factors Influencing Immunogenicity in Biologics

Several patient-specific and product-related factors contribute to the immunogenicity of biologic therapies:

- **Patient Genetics:** Genetic variability among patients, such as differences in immune system-related genes (e.g., HLA genes), can influence their likelihood of developing immune responses to biologic therapies. Pharmacogenomic profiling can help predict which patients may be at greater risk for developing ADAs and guide treatment choices accordingly.
- **Treatment History:** Previous exposure to biologics or other immunotherapies may alter the immune system's response. For example, patients who have been treated with other monoclonal antibodies may have a heightened immune response to a new biologic, particularly if it has structural similarities to the previous one.
- **Therapeutic Agent Characteristics:** The structure, source (human, chimeric, or murine), and formulation of the biologic drug significantly influence its immunogenic potential. Fully human biologics tend to provoke less immune response compared to chimeric or murine proteins. Additionally, the choice of excipients used in drug formulations can also impact immunogenicity.

Personalized Medicine Approaches to Mitigate Immunogenicity

Personalized medicine focuses on tailoring therapeutic interventions based on individual patient characteristics such as genetics, environment, and lifestyle. When it comes to biologic therapies, immunogenicity—the ability of therapeutic agents to provoke an immune response—is a significant concern that can reduce the efficacy of treatment and increase the risk of adverse events. In personalized medicine, strategies aimed at mitigating immunogenicity are increasingly being employed to optimize biologic therapies and improve patient outcomes.[5] These strategies involve a deep understanding of individual patient profiles and the careful selection or modification of therapeutic agents.

Genetic Profiling to Predict Immunogenicity Risk

Genetic variability plays a critical role in determining how an individual's immune system responds to biologic therapies. Certain genetic factors, particularly polymorphisms in genes involved in immune system regulation, can influence the likelihood of developing anti-drug antibodies (ADAs). Personalized medicine utilizes genetic profiling to identify these variations and predict a patient's immune response to biologics.

- **Human Leukocyte Antigen (HLA) Genotyping:** The HLA complex is essential for presenting antigens to T cells and plays a crucial role in the immune response to biologics. Certain HLA alleles have been linked to an increased risk of immunogenicity. For example, specific HLA-DQA1 or HLA-DQB1 alleles have been associated with the development of ADAs in patients receiving monoclonal antibodies (mAbs). By performing pre-treatment HLA typing, clinicians can identify high-risk patients and make informed decisions about therapy choices or closely monitor for immune reactions.
- **Pharmacogenomic Testing:** Pharmacogenomic testing can identify patients who are genetically predisposed to react to certain biologics. Genetic polymorphisms in genes encoding cytokines, immune modulators, or drug-metabolizing enzymes may influence how a patient's immune system perceives a biologic therapy. For example, variations in the IL-10 or TNF-α gene may affect a patient's susceptibility to inflammatory responses, which could influence their risk of developing ADAs. Identifying these genetic markers allows clinicians to select biologic therapies less likely to provoke immune responses.
- **Biomarker Discovery:** Beyond genetic profiling, identifying specific biomarkers of immunogenicity is an essential step in predicting and preventing immune responses. By measuring circulating cytokines, immune cell activation markers, and ADAs early in treatment, clinicians can anticipate immune-related adverse events and make adjustments before the immune response worsens.

Biologic Engineering to Reduce Immunogenicity

One of the most important strategies for mitigating immunogenicity in biologic therapies is the engineering of the biologic product itself. [6] Advances in biologic engineering techniques have allowed for the development of drugs with reduced immunogenic potential, thus improving the safety and efficacy of treatments.

- **Humanization of Monoclonal Antibodies:** Chimeric monoclonal antibodies, which contain both human and murine components, are more likely to provoke an immune response due to their non-human components. Humanized antibodies, on the other hand, are engineered to have a greater proportion of human sequences, thereby reducing the likelihood of immune recognition. The most advanced forms are fully human antibodies, which are derived from human sources and have minimal immunogenic potential. The development of fully human antibodies, through techniques like phage display or transgenic mice, has helped mitigate immunogenicity in many biologic therapies.

Kumar N & Prasad P
Rec. Trends Pharm. Tech. Ind. 2025; 7(1)

46

- **Glycosylation Modifications:** The glycosylation patterns of biologic drugs—the process of adding sugar molecules to the protein structure—can affect their immunogenicity. Aberrant glycosylation can trigger immune responses, while proper glycosylation can reduce the likelihood of immunogenicity. By modifying the glycosylation of biologics, scientists can optimize their pharmacokinetics, improve their stability, and reduce their immunogenic potential. For example, modifying the Fc region of monoclonal antibodies can help improve their therapeutic activity while minimizing immune system activation.

- **Fc Region Engineering:** The Fc region of antibodies plays a critical role in immune activation and clearance. By engineering the Fc region to reduce immune system activation, biologic drugs can avoid triggering unwanted immune responses. This approach can reduce the formation of ADAs and improve the half-life of biologic therapies, allowing for less frequent dosing. For example, Fc engineering can alter the binding affinity to Fc receptors and complement proteins, helping to minimize unwanted immune activation.

- **Bispecific and Trispecific Antibodies:** In some cases, bispecific antibodies (which can bind to two different targets) or trispecific antibodies (which can bind to three targets) are engineered to improve therapeutic efficacy and reduce immunogenicity. These antibodies often use a combination of human and carefully optimized non-human components that are less likely to induce immune responses, while enhancing the therapeutic effects, particularly in cancer therapy.

Immunosuppressive Strategies to Prevent Immune Responses

In some cases, immunosuppressive therapies may be employed in conjunction with biologic treatments to reduce the risk of immunogenicity. These approaches aim to modulate the immune system to prevent the development of ADAs or reduce the severity of hypersensitivity reactions.

- **Pre-Treatment Immunosuppression:** In certain patients, particularly those with autoimmune diseases, a short course of immunosuppressive therapy before starting biologic treatment may help prevent immune responses. Drugs such as corticosteroids, methotrexate, or calcineurin inhibitors can help dampen the immune system's reaction to biologics and reduce the risk of ADAs.[7] However, the use of immunosuppressive drugs must be carefully managed to avoid compromising the patient's immune defenses against infections.

- **Immunosuppressive Co-Therapies:** For patients who develop ADAs despite pre-treatment screening and biologic engineering, co-treatment with immunosuppressive drugs may be necessary. Medications such as rituximab (which depletes B cells

responsible for producing ADAs) or mycophenolate mofetil (which inhibits T and B cell activation) can help reduce ADA production and allow the patient to continue biologic therapy. Close monitoring of immune function and infection risks is essential when using immunosuppressive co-therapy.

Personalized Treatment Monitoring

Personalized medicine also includes the ongoing monitoring of patients during biologic therapy to identify early signs of immunogenicity. Regular assessment of drug levels, ADA presence, and immune responses helps clinicians make adjustments to the treatment plan and avoid potential complications.

- **Anti-Drug Antibodies (ADA) Testing:** Periodic testing for ADAs in patients undergoing biologic therapy can identify immune responses early, allowing for timely intervention. If ADAs are detected, clinicians may adjust the dosing schedule, switch to a different biologic, or consider additional immunosuppressive therapies.

- **Pharmacokinetic Monitoring:** In addition to ADA testing, pharmacokinetic (PK) monitoring is critical to assessing the impact of immunogenicity on drug levels in the body. Changes in drug clearance rates due to ADA formation may require dose adjustments. PK monitoring also helps ensure that biologic drugs maintain therapeutic levels in the patient's system.

Challenges and Future Directions

Despite significant advancements in personalized medicine and efforts to mitigate immunogenicity in biologic therapies, several challenges remain. These challenges encompass issues related to genetic variability, regulatory hurdles, the complexity of biologic production, and patient management.[8] However, as the field continues to evolve, emerging technologies and strategies hold promise for addressing these challenges and improving the outcomes of biologic therapies.

Challenges in Mitigating Immunogenicity

Genetic and Immunological Variability

One of the most significant challenges in personalized medicine is the genetic variability among patients, which can lead to unpredictable immune responses to biologics. While pharmacogenomic profiling can help predict immunogenicity risk, the complexity of the human immune system makes it difficult to anticipate all potential reactions. Additionally, immune responses are influenced by environmental factors, comorbid conditions, and prior treatments, further complicating prediction models.

- **Complexity of Immune Responses:** The immune system is highly intricate, with numerous factors influencing how it perceives biologic therapies. For example, two

47

Kumar N & Prasad P
Rec. Trends Pharm. Tech. Ind. 2025; 7(1)

patients with similar genetic profiles might still respond differently to the same biologic. Understanding the nuanced interaction between the immune system and biologics remains a major challenge in personalized medicine.

- **Multifactorial Nature of Immunogenicity:** Immunogenicity is not solely determined by genetic factors; other influences such as microbial flora, infections, or autoimmune conditions can also alter immune responses. This multifactorial nature makes it difficult to establish universal biomarkers or genetic markers for predicting immunogenicity.

Biologic Complexity and Heterogeneity

The complexity and heterogeneity of biologic therapies pose additional challenges in predicting and managing immunogenicity. Biologic drugs, particularly monoclonal antibodies, are large and complex molecules, which can be affected by slight changes in their structure or manufacturing process.

- **Manufacturing Variability:** The production process for biologics, which often involves mammalian cell culture, can introduce subtle variations in the final product. Differences in glycosylation patterns, protein folding, or the presence of contaminants can affect the immunogenicity of the drug.[9] Ensuring consistency and quality control throughout the manufacturing process is crucial for minimizing immunogenicity but remains a challenge.
- **Formulation and Storage:** The formulation and storage of biologics can also impact their immunogenic potential. Conditions such as temperature fluctuations during storage or improper handling can lead to the aggregation of biologic molecules, which may increase their immunogenicity. Ensuring the stability and integrity of biologic drugs during distribution and administration is an ongoing challenge.

Regulatory and Ethical Considerations

Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), play an essential role in approving biologic therapies and ensuring their safety and efficacy. However, the approval process for biologics is complex, and ensuring that immunogenicity is adequately assessed is a challenge.

- **Lack of Standardized Assays:** One challenge in immunogenicity testing is the absence of standardized assays to assess immune responses to biologics. The variability in testing methods can result in inconsistent data, making it difficult to compare studies or predict long-term outcomes for patients.[10]
- **Regulatory Hurdles:** Personalized medicine approaches for biologics often face regulatory hurdles, as current regulatory frameworks are designed for traditional, one-size-fits-all treatments. The need for individualized dosing, monitoring, and treatment plans requires a shift in how biologics are evaluated and approved by regulatory agencies.
- **Ethical Considerations:** The use of genetic testing in personalized medicine raises ethical concerns, particularly with regard to patient privacy, informed consent, and potential discrimination. Ethical frameworks need to evolve to ensure that personalized treatment strategies are implemented in a way that respects patient rights and autonomy.

Future Directions in Mitigating Immunogenicity

Advances in Immunogenicity Prediction Models

Future research will likely focus on improving the prediction of immunogenicity in biologic therapies by developing more sophisticated models that integrate genetic, immunological, and clinical data. Machine learning and artificial intelligence (AI) technologies have the potential to enhance predictive modeling by identifying patterns in large datasets and offering personalized risk assessments for individual patients.[11,12]

- **Multi-Omics Approaches:** The integration of genomic, proteomic, and metabolomic data—collectively known as multi-omics—could provide a more comprehensive understanding of how individual patients' immune systems interact with biologic drugs. This approach could lead to more accurate predictions of immunogenicity and the development of personalized treatment plans.
- **AI and Big Data:** The use of AI in analyzing large-scale patient data, including genetic profiles and clinical outcomes, can help identify new biomarkers of immunogenicity and improve the design of biologic therapies. AI algorithms could also help streamline the process of developing biologics with reduced immunogenic potential.

Enhanced Biologic Engineering and Manufacturing

As biologic therapies continue to evolve, improvements in biologic engineering and manufacturing are expected to reduce immunogenicity further.

- **Next-Generation Monoclonal Antibodies:** New technologies such as bispecific antibodies and nanobodies, which are smaller and potentially less immunogenic, offer exciting avenues for reducing immune responses. Furthermore, engineered antibodies that selectively target immune checkpoints or modulate immune cell activity could help reduce the likelihood of unwanted immune activation.
- **Cell-Based Manufacturing and Quality Control:** Advancements in cell-based production systems and quality control techniques will improve the consistency

Kumar N & Prasad P
Rec. Trends Pharm. Tech. Ind. 2025; 7(1)

48

and purity of biologics. Techniques such as CRISPR gene editing may allow for more precise modifications to the DNA of production cells, reducing the chances of unwanted variability in the final product.

- **Smart Delivery Systems:** The development of smart drug delivery systems that can target biologics more precisely to specific tissues or cells could minimize the exposure of the immune system to non-targeted biologics, thus reducing the risk of immunogenicity.

Personalized Treatment and Monitoring

The future of biologic therapy lies in the personalized approach to treatment and ongoing monitoring. As the field of personalized medicine expands, the ability to adjust treatment in real-time based on a patient's evolving immune response will become increasingly important.

- **Real-Time Monitoring of Immunogenicity:** Advances in biomarkers and diagnostic tools will enable clinicians to monitor immune responses more effectively during biologic therapy. The ability to detect and measure the development of ADAs early will allow for timely adjustments to the treatment plan, such as switching biologics or modifying dosing regimens.
- **Personalized Dosing and Administration:** In the future, biologic therapies may be tailored not just to a patient's genetics but also to their immune system's response. Personalized dosing regimens that account for a patient's risk of immunogenicity and their drug levels in the body could improve the safety and efficacy of biologic treatments.
- **Precision Immunosuppressive Strategies:** The development of precision immunosuppressive therapies that target specific immune pathways involved in ADAs and hypersensitivity reactions could help mitigate immunogenicity without compromising the patient's overall immune function.

Conclusion

Immunogenicity is a critical consideration in the development and application of biologic therapies. Personalized medicine offers an exciting opportunity to tailor treatments based on individual patient characteristics, including their immunogenic profiles. By integrating genetic testing, biomarker discovery, and biologic engineering, healthcare providers can reduce the risks associated with immune responses, improving the safety and efficacy of treatments. As our understanding of immunogenicity evolves, personalized medicine will continue to shape the future of healthcare, leading to more effective, patient-specific therapies.

References

1. Zhou Q, Chirmule N, Sumida S, et al. Immunogenicity of monoclonal antibodies: assessment and regulation. Drug Discovery Today. 2016;21(7):1099–1106. doi: 10.1016/j.drudis.2016.01.025.
2. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet. 2009;373(9668):1033–1040. doi: 10.1016/S0140-6736(09)60209-4.
3. Knee M, Abels J, Bruse N, et al. Personalized medicine: A new approach for the treatment of autoimmune diseases. Autoimmun Rev. 2017;16(7):737–748. doi: 10.1016/j.autrev.2017.04.013.
4. Viel L, Kervern M, Quéré G, et al. Immunogenicity of therapeutic monoclonal antibodies: A review of the regulatory guidelines. Biol. Drugs. 2017;31(2):65–72. doi: 10.1007/s10555-017-9760-2.
5. Zhang F, Zhang Y, Wang S, et al. The impact of genetic polymorphisms on the immunogenicity of biologics: Implications for personalized medicine. Pharmacogenomics J. 2017;17(1):15–23. doi: 10.1038/tpj.2016.3.
6. Kumar V, Narang A. Biologic therapy and immunogenicity: A key challenge in the treatment of chronic diseases. J Pharmacol Exp Ther. 2019;368(2):193–202. doi: 10.1124/jpet.118.253249.
7. Mellstedt H, Jönsson F, Ygberg S, et al. Immunogenicity of therapeutic monoclonal antibodies: Relevance for personalized medicine in oncology. Ther Adv Med Oncol. 2016;8(3):179–193. doi: 10.1177/1758834016638881.
8. Kang K, Ali S, Gokhale A, et al. Advances in biologic drug engineering to reduce immunogenicity. Biotechnol Adv. 2018;36(1):68–78. doi: 10.1016/j.biotechadv.2017.11.003.
9. Lefebvre C, Ringrose R, Lee S, et al. Genetic polymorphisms and the immunogenicity of biologic agents: Opportunities for patient-tailored therapy. Biol. Ther. 2015;61(3):383–391. doi: 10.1007/s11356-015-6061-6.
10. Jiang J, Zeng L, Li Z, et al. Immune response to biologics and the risk of developing anti-drug antibodies in autoimmune diseases. Autoimmun Rev. 2015;14(7):586–593. doi: 10.1016/j.autrev.2015.02.003.
11. Wang M, Zhang W, Lei Q, et al. Personalized medicine approaches to immunogenicity in monoclonal antibody therapy. Front Immunol. 2020;11:586. doi: 10.3389/fimmu.2020.00586.
12. Richman LP, O'Shaughnessy JA. The role of monoclonal antibodies in personalized cancer therapy. Clin Cancer Res. 2019;25(22):6687–6694. doi: 10.1158/1078-0432.CCR-19-1157.